Antihypertensive prescribing patterns in non-dialysis dependent chronic kidney disease: Findings from the Salford Kidney Study

doi:10.5527/wjn.v12.i5.168

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2607)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-12) series.

Item

Count

PDF

WORD

HTML

1284

Figures (1-4)

178

Tables (1-12)

222

Sum=1741

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

143

Download

291

Sum=434

Publishing Process of This Article

Item

Count

Browse

120

Download

239

Sum=359

Dec 25, 2023 (publication date) through Nov 2, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Nephrol. Dec 25, 2023; 12(5): 168-181
Published online Dec 25, 2023. doi: 10.5527/wjn.v12.i5.168

Table 7 Number of patients prescribed with each antihypertensive class at baseline and the 12-mo and 24-mo follow-ups

Antihypertensive class	Baseline, n = 1708¹	12-mo follow-up, n = 1708¹	24-mo follow-up, n = 1708¹	P value¹
Diuretic (thiazide and loop)	895 (52.4)	874 (51.2)	839 (49.1)	0.153
CCB (dihydropyridine)	696 (40.7)	710 (41.6)	646 (37.8)	0.063
CCB (non- dihydropyridine)	83 (4.9)	74 (4.3)	75 (4.4)	0.719
Beta blocker	588 (34.4)	581 (34.0)	560 (32.8)	0.573
Alpha blocker	421 (24.6)	433 (25.4)	394 (23.1)	0.281
Central agent	81 (4.7)	90 (5.3)	66 (5.0)	0.779
Vasodilator	18 (1.1)	14 (0.8)	18 (1.1)	0.724
RAS blocker	1076 (63.0)	1077 (63.1)	1056 (61.8)	0.417
Dual RAS blockers	99 (5.8)	127 (7.4)	122 (7.1)	0.127
Spironolactone/eplerenone	58 (3.4)	49 (2.9)	43 (2.5)	0.309

¹Absolute number for frequencies (percentages). The P values were calculated by the χ² test.

CCB: Calcium channel blocker, RAS: Renin angiotensin system.

Citation: Chinnadurai R, Wu HHL, Abuomar J, Rengarajan S, New DI, Green D, Kalra PA. Antihypertensive prescribing patterns in non-dialysis dependent chronic kidney disease: Findings from the Salford Kidney Study. World J Nephrol 2023; 12(5): 168-181
URL: https://www.wjgnet.com/2220-6124/full/v12/i5/168.htm
DOI: https://dx.doi.org/10.5527/wjn.v12.i5.168